LENZ Therapeutics, Inc. (NASDAQ: LENZ)

LENZ Therapeutics, Inc. is a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve vision. The company operates in the ophthalmic pharmaceutical industry with a primary focus on treating presbyopia, an age-related loss of near vision.

The company generates revenue primarily from the sale of VIZZ (aceclidine ophthalmic solution) 1.44 percent in the United States. Sales are made through direct to eye care professional representatives, shipments to an electronic pharmacy partner, and broad availability in retail pharmacies. Revenue also comes from upfront payments, milestone payments and royalties from international licensing and distribution agreements for VIZZ in regions such as Greater China, South Korea and Southeast Asia, Canada and the Middle East. The product is sold on a self pay basis without third party reimbursement.

LENZ Therapeutics, Inc. holds a differentiated position in the presbyopia treatment market as the first and only FDA approved aceclidine based eye drop. The product benefits from patent protection extending to 2044 and five years of new chemical entity exclusivity in the United States expiring in July 2030. Key competitors include AbbVie with Vuity, Orasis with Qlosi, Amneal Therapeutics with a generic version of Vuity and Tenpoint Therapeutics with Yuvezzi. Competitive advantages stem from aceclidine's pupil selective mechanism of action which improves near vision for up to ten hours without a meaningful impact on distance vision, a strong intellectual property portfolio and an experienced management team with a track record of launching ophthalmic and consumer products.

The company serves eye care professionals such as optometrists and ophthalmologists who prescribe VIZZ and presbyopic consumers who purchase the product through retail pharmacies and electronic pharmacy partners. Specific customer names are not disclosed in the filing.